



Sociedade
Brasileira de
Infectologia

The Brazilian Journal of INFECTIOUS DISEASES

www.elsevier.com/locate/bjid



Original Article

Diagnostic performance of the RSNA-proposed classification for COVID-19 pneumonia versus pre-pandemic controls

Q1 Cauã O. Rocha ^{a,b,*}, Tássia A.D. Prioste ^a, Carlo S. Faccin ^a, Luciano Folador ^a, Mateus S. Tonetto ^{a,b}, Pedro G. Knijnik ^c, Natalia B. Mainardi ^c, Rogério B. Borges ^d, Tiago S. Garcia ^{a,b}

^a Radiology Department, Hospital de Clínicas de Porto Alegre (HCPA), RS, Brazil

^b Graduate Program in Pulmonary Sciences, Universidade Federal do Rio Grande do Sul, RS, Brazil

^c School of Medicine, Universidade Federal do Rio Grande do Sul, RS, Brazil

^d Biostatistics Unit, Graduate Research Group (GPPG), Hospital de Clínicas de Porto Alegre, RS, Brazil

ARTICLE INFO

Article history:

Received 23 August 2021

Accepted 23 November 2021

Available online xxx

Keywords:

Chest CT

COVID-19 pneumonia

RSNA classification

Pre-pandemic controls

ABSTRACT

Objective: To evaluate the diagnostic accuracy of the Radiological Society of North America (RSNA) classification system for coronavirus disease 2019 (COVID-19) pneumonia compared to pre-pandemic chest computed tomography (CT) scan images to mitigate the risk of bias regarding the reference standard.

Materials and methods: This was a retrospective, cross-sectional, diagnostic test accuracy study. Chest CT scans, carried out from May 1 to June 30, 2020, and from May 1 to July 17, 2017, were consecutively selected for the COVID-19 (positive reverse transcription-polymerase chain reaction [RT-PCR] for severe acute respiratory syndrome coronavirus 2 result) and control (pre-pandemic) groups, respectively. Four expert thoracic radiologists blindly interpreted each CT scan image. Sensitivity and specificity were calculated.

Results: A total of 160 chest CT scan images were included: 79 in the COVID-19 group (56 [43.5–67] years old, 41 men) and 81 in the control group (62 [52–72] years old, 44 men). Typically, an estimated specificity of 98.5% (95% confidence interval [CI] 98.1%–98.4%) was obtained. For the indeterminate classification as a diagnostic threshold, an estimated sensitivity of 88.3% (95% CI 84.7%–91.7%) and a specificity of 79.0% (95% CI 74.5%–83.4%), with an area under the curve of 0.865 (95% CI 0.838–0.895), were obtained.

Conclusion: The RSNA classification system shows strong diagnostic accuracy for COVID-19 pneumonia, even against pre-pandemic controls. It can be an important aid in clinical

This study was financed in part by the Fundo de Incentivo à Pesquisa (FIPE)/HCPA.

The authors declare no conflict of interest associated with this manuscript.

* Corresponding author.

E-mail address: corocha@hcpa.edu.br (C.O. Rocha).

<https://doi.org/10.1016/j.bjid.2021.101665>

1413-8670/© 2021 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

decision-making, especially when a typical or indeterminate pattern is found, possibly advising retesting following an initial negative RT-PCR result and streamlining early management and isolation.

© 2021 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

1 Introduction

2 Coronavirus disease 2019 (COVID-19), caused by the severe
3 acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has
4 spread globally, becoming an ongoing pandemic responsible
5 for more than four million deaths worldwide and more than
6 550,000 casualties in Brazil, the second most affected country
7 in the world to date.¹ Consequently, computed tomography
8 (CT) of the chest has been employed to assist in the diagnosis
9 and assessment of potential complications and prognosis of
10 patients with COVID-19.^{2,3} Since findings associated with
11 COVID-19 pneumonia can be found in other lung diseases,⁴
12 some radiological societies have published guidelines with
13 objective criteria to improve accuracy and reproducibility of
14 chest CT findings, notably the Radiological Society of North
15 America (RSNA) expert consensus,⁵ among others.^{6,7}

16 The RSNA classification system for reporting COVID-19 pneu-
17 monia classified chest CT findings into four categories (negative,
18 atypical, indeterminate, and typical; [Table 2](#)). Studies have
19 shown its noteworthy diagnostic performance with specific
20 diagnostic thresholds (indeterminate and typical), as well as
21 moderate-to-substantial inter-reader agreement, mostly adopt-
22 ing the SARS-CoV-2 reverse transcription-polymerase chain
23 reaction (RT-PCR) test as the reference diagnostic standard.^{8–17}

24 According to published meta-analyses,^{18–20} the quality of
25 early articles designed to assess the accuracy of chest CT in the
26 diagnosis of pneumonia caused by SARS-CoV-2 was considered
27 suboptimal. Limited adherence to reporting guidelines and a
28 high risk of bias, especially regarding patient selection and the
29 reference diagnostic standard, have been reported. A more recent
30 meta-analysis confirmed a high risk of bias regarding the refer-
31 ence test, specifically because RT-PCR testing was not repeated
32 in all patients with an initial negative result in some studies.¹⁷
33 Concern over chest CT diagnostic accuracy during overlapping
34 seasonal flu caused by influenza has also been raised.^{17,20}

35 To address these concerns, a single-center, retrospective,
36 cross-sectional, diagnostic test accuracy study was conducted
37 to evaluate the RSNA classification system for reporting COVID-
38 19 pneumonia⁵ using chest CT images of patients with RT-PCR-
39 confirmed SARS-CoV-2 infection and pre-pandemic samples,
40 true negatives for COVID-19, as controls. The RSNA classifica-
41 tion may be an important aid in clinical decision-making,
42 encouraging retesting following an initial negative RT-PCR
43 result and streamlining early management and isolation.

44 Material and Methods

45 This single-center, retrospective, cross-sectional study was
46 approved by the local institutional review board. Informed

consent was waived because no risk was presented to the par- 47
48 ticipants. All relevant clinical information was obtained from
49 our hospital's electronic medical records system.

Participant selection

COVID-19 group

51 From May 1 through June 30, 2020, chest CT scan images of 52
53 inpatients, from both wards and emergency departments,
54 with confirmed COVID-19 by at least one positive RT-PCR
55 result within seven days of the CT scan date were consecu-
56 tively selected. This period was chosen to match the initial
57 regional rising incidence period of COVID-19²¹ as well as the
58 historic regional peak incidence periods of influenza pneumo-
59 nia and acute respiratory distress syndrome.²²

Control group

60 From May 1 through July 17, 2017, chest CT scan images of 61
62 inpatients, as requested by emergency department physi-
63 cians, that had at least one of the following text descriptors
64 were consecutively selected:

- 65 1. Clinical information: pneumonia, infection, respiratory, 65
66 dyspnea, cough, fever, acute, flu, viral, hypoxemia, tachyp- 66
67 nea, shortness of breath, bronchopneumonia (BCP), desa- 67
68 turation, viral; 68
- 69 2. Radiological report: pneumonia, inflammatory, infectious, 69
70 ground glass, viral. 70

Exclusion criteria

71 The following exclusion criteria were applied to the COVID-19 72
73 group only:

- 74 1. RT-PCR results were indeterminate or unavailable (e.g., 74
75 external analysis). 75

76 The following exclusion criteria were applied to both 76
77 groups:

- 78 1. Patient <18 years old; 78
- 79 2. Technically limited/low-quality images (e.g., severe respi- 79
80 ratory motion artifacts). 80

Index test and reference standard

81 Chest CT scans were routinely requested at the discretion of 82
83 the attending physician considering the institutional proto-
84 col, pneumonia severity criteria, laboratory tests, and comor-
85 bilities. 85

86 RT-PCR-positive results were considered as the reference 86
87 diagnostic standard for COVID-19 diagnosis. It was a two-site 87

88 test, oropharyngeal and nasopharyngeal swab, with analysis
89 performed by the institution's own laboratory.

90 The control group selection period, approximately two
91 years prior to the emergence of COVID-19, was considered the
92 reference standard for the absence of the disease. Search and
93 selection were performed using a business intelligence soft-
94 ware in our Radiology Information System/Picture Archiving
95 and Communication System (RIS/PACS) database.

96 CT acquisition technique

97 Images were obtained using an eight-row multidetector CT
98 (MDCT) scanner (BrightSpeed Edge, GE Medical Systems,
99 USA), a 16-row MDCT scanner (Brilliance 16, Philips Health-
100 care, the Netherlands), or a 64-row MDCT scanner (Aquilion
101 64, Toshiba Medical Systems, Japan), with patients in the
102 supine position and at full inspiration. All scans were volu-
103 metric acquisitions (slice thickness: 1.0–2.0 mm) and were
104 reconstructed with a high-spatial-frequency algorithm.
105 Images were stored and analyzed using PACS (IMPAX
106 6.6.1.3525, Agfa HealthCare, Belgium). When used, iodinated
107 nonionic intravenous contrast medium was injected into a
108 peripheral vein at a dose of 1–2 mL/kg of body weight.

109 CT image reading and classification

110 Chest CT scan findings were anonymized for patient identifi-
111 cation/information and scanning date and then codified and
112 randomly sorted in a predefined sequence by our PACS oper-
113 ated by the authors who did not participate in the interpreta-
114 tion. For convenience, only the axial series (lung window) of
115 each scan was used.

116 The readers were four thoracic radiologists (reader 1 [CSF],
117 15 years of experience; reader 2 [LF], 8 years of experience;
118 reader 3 [TSG], 20 years of experience; and reader 4 [MST],
119 10 years of experience) who were blinded to each other and to
120 patient identification, clinical/laboratory information, previ-
121 ous imaging tests, RT-PCR results, and scanning date.

All chest CT scans were consecutively interpreted once 122
and individually by all four reviewers in a predefined 123
sequence. Radiological findings were classified according to 124
the four categories proposed by the RSNA consensus 125
(Table 1).⁵ No final consensus or agreement between readers 126
was sought. 127

Sample size

The sample size was calculated to estimate the sensitivity 129
and specificity of the classification proposed by the RSNA to 130
diagnose SARS-CoV-2 pneumonia using the formulas 131
described by Buderer (1996).²³ For a 95% confidence interval 132
(CI), a desired precision of 10%, and a sensitivity and specific- 133
ity of 75%, a sample size of 145 participants was reached. The 134
final sample size was 162 participants, with 10% added for 135
possible losses. 136

Statistical analysis

Qualitative variables were expressed as absolute and relative 138
frequencies (n [%]), and quantitative variables as median and 139
first and third quartiles (median [Q₁–Q₃]). The distribution of 140
quantitative variables was assessed by graphical analysis of 141
the histogram and the quartile–quartile plot. 142

Associations between qualitative variables were assessed 143
using the Pearson χ^2 test of independence with Yates' conti- 144
nuity correction. Fleiss kappa statistic²⁴ was used to evaluate 145
inter-reader classification agreement among the four readers. 146

A generalized linear mixed-effects model with binomial 147
distribution was used to estimate the predicted probability of 148
positivity for COVID-19. The estimated probabilities were 149
then used to calculate a receiver operating characteristic 150
(ROC) curve, which computed the area under the curve (AUC), 151
sensitivity, and specificity. The AUC was calculated using the 152
Wilcoxon nonparametric approach by comparing the pre- 153
dicted probabilities of all discordant pairs of observations.²⁵ 154
Empirical bootstrap (with 10,000 replications) was used to 155

Table 1 – Baseline variables and clinical data.

Baseline	All (n = 160)	COVID-19 (n = 79)	Control (n = 81)
Age, years	59 (44-70)	56 (43.5-67)	62 (52-72)
Male sex	85 (53.1)	41 (51.9)	44 (54.3)
Respiratory/pneumonia signs and symptoms ^a	130 (81.2)	72 (91.1)	58 (71.6)
Comorbidities ^b			
Cancer	48 (29.6)	4 (4.9)	44 (54.3)
Primary lung cancer	9 (5.6)	0	9 (11.1)
Chronic lung diseases	33 (20.6)	12 (15.2)	21 (25.9)
Smoking	68 (42.5)	22 (27.8)	46 (56.8)
Obesity (BMI ≥ 30)	26 (16.2)	19 (24.1)	7 (8.6)
Hypertension	76 (47.5)	41 (51.9)	35 (43.2)
Coronary artery disease	10 (6.2)	5 (6.3)	5 (6.2)
Congestive heart failure	13 (8.1)	4 (5.1)	9 (11.1)
Diabetes	34 (21.2)	21 (26.6)	13 (16.0)
Hematologic diseases	16 (10.0)	3 (3.8)	13 (16.0)
Immunocompromised	17 (10.6)	7 (8.9)	10 (12.3)

^a Respiratory/pneumonia signs and symptoms = cough, fever, chest pain, dyspnea, tachypnea, hypoxemia, sputum.

^b Comorbidities = cancer, chronic lung diseases, smoking, obesity (body mass index, BMI > 30), hypertension, coronary artery disease, congestive heart failure, diabetes, hematologic diseases, immunosuppression.

Table 2 – Radiological Society of North America-Proposed Reporting Language (5).

CT category	Imaging findings
Typical	Peripheral, bilateral GGO ^a with or without consolidation or visible intralobular lines (“crazy-paving”) Multifocal GGO of rounded morphology with or without consolidation or visible intralobular lines (“crazy-paving”) Reverse halo sign or other findings of organizing pneumonia (seen later in the disease)
Indeterminate	Absence of typical features and presence of: Multifocal, diffuse, perihilar, or unilateral GGO with or without consolidation, lacking a specific distribution and being nonrounded or nonperipheral. Few, very small GGO with a nonrounded and nonperipheral distribution
Atypical	Absence of typical or indeterminate features and presence of: Isolated lobar or segmental consolidation without GGO Discrete small nodules (centrilobular; “tree-in-bud”) Lung cavitation Smooth interlobular septal thickening with pleural effusion
Negative	No features to suggest pneumonia.

^a GGO = ground-glass opacity.

156 evaluate the 95% CIs. Analyses were performed using the R
157 software, version 4.0.3.²⁶

158 Results

159 Participant selection and clinical baseline

160 COVID-19 group

161 Within the chosen period, 82 chest CT scan images met the
162 COVID-19 group inclusion criteria, with 79 remaining after
163 excluding three for technical limitations.

164 Control group

165 For the control group, 83 CT scan images met the inclusion
166 criteria, with 81 remaining after excluding one underage
167 patient at the time of scanning and one for technical
168 limitations.

169 Clinical baseline

170 The male sex relative frequency and median patient age
171 were 51.9% and 56 (43.5–67) years in the COVID-19 group
172 and 54.3% and 62 (52–72) years in the control group, with
173 $p = 0.8819$ and 0.0693 , respectively. In the COVID-19 group,
174 the median time between RT-PCR sample collection and
175 chest CT scan was one day (0–2 days), whereas the
176 median time between symptom onset and chest CT scan
177 was eight days (5–16 days). Population baseline and clinical
178 data are summarized in [Table 1](#).

CT image reading and classification 179
The results of the CT scan classification for each reader are 180
shown in [Table 3](#). 181

Statistical analysis 182

Diagnostic performance 183

Diagnostic accuracy was evaluated according to different possible 184
positivity criteria ([Table 4](#)): 185

1. Typical classification ([Fig. 2](#)) as a positive test for COVID-19 186
pneumonia, with an estimated sensitivity of 52.2% (95% CI 187
47.9%–52.4%), a specificity of 98.5% (95% CI 98.1%–98.4%), 188
an AUC of 0.781 (95% CI 0.731–0.785), a positive predictive 189
value (PPV) of 97.3% (95% CI 94.2%–99.4%), and a negative 190
predictive value (NPV) of 67.9% (95% CI 63.1%–72.0%). 191
2. Indeterminate classification ([Fig. 3](#)) as a positive test for 192
COVID-19 pneumonia, with an estimated sensitivity of 193
36.1% (95% CI 35.8%–38.9%), a specificity of 80.5% (95% CI 194
79.2%–80.7%), an AUC of 0.583 (95% CI 0.579–0.598), a PPV 195
of 64.1% (95% CI 56.1%–71.2%), and an NPV of 56.2% (95% 196
CI 51.6%–60.7%). 197
3. Typical or indeterminate classification as a positive test for 198
COVID-19 pneumonia, with an estimated sensitivity of 199
88.3% (95% CI 84.7%–91.7%), a specificity of 79.0% (95% CI 200
74.5%–83.4%), an AUC of 0.865 (95% CI 0.838–0.895), a PPV 201
of 80.5% (95% CI 76.4%–85.0%), and an NPV of 87.4% (95% 202
CI 83.4%–91.2%). 203

The ROC curve is shown in [Fig. 1](#). 204

Atypical ([Fig. 4](#)) and negative classifications were evalu- 205
ated as criteria for an alternative diagnosis, returning specific- 206
ities of 93.4% (95% CI 90.2%–96.0%) and 94.8% (95% CI 71.7% 207
–97.2%), respectively. 208

Predictive values computed for each scenario are shown in 209
[Table 5](#). 210

Inter-reader agreement 211

Inter-reader overall agreement analysis, including all four 212
categories, demonstrated a moderate Fleiss kappa value of 213
0.527 (95% CI 0.490–0.564). Agreement was highest for the typ- 214
ical classification, with a substantial Fleiss kappa value of 215
0.648 (95% CI 0.584–0.711), and lowest for the indeterminate 216
classification, with a fair Fleiss kappa value of 0.383 (95% CI 217
0.320–0.446) ([Table 3](#)). 218

Discussion 219

The RSNA-proposed chest CT imaging classification can provide 220
excellent diagnostic accuracy for COVID-19 pneumonia, 221
with high specificity and sensitivity, depending on the chosen 222
diagnostic threshold. The classification also showed a note- 223
worthy inter-reader agreement when tested against pre-pandemic 224
controls affected by diverse respiratory diseases and 225
treated at the emergency department, specifically during the 226
regional peak incidence periods of influenza pneumonia and 227
acute respiratory distress syndrome. 228

Our findings suggest that the typical pattern is highly asso- 229
ciated with COVID-19 pneumonia, even when compared to 230

Table 3 – CT results and inter-reader agreement (Fleiss kappa).

CT results	All (n = 160)	COVID-19 (n = 79)	Control (n = 81)	Fleiss kappa [95% CI]
All categories				0.527 [0.490-0.564]
Typical				0.648 [0.584-0.711]
Reader 1	39	39 (49.4)	0 (0.0)	
Reader 2	33	31 (39.2)	2 (2.5)	
Reader 3	56	54 (68.4)	2 (2.5)	
Reader 4	42	41 (51.9)	1 (1.2)	
Indeterminate				0.383 [0.320-0.446]
Reader 1	61	35 (44.3)	26 (32.1)	
Reader 2	33	29 (36.7)	4 (4.9)	
Reader 3	34	19 (24.1)	15 (18.5)	
Reader 4	49	31 (39.2)	18 (22.2)	
Atypical				0.565 [0.502-0.629]
Reader 1	50	3 (3.8)	47 (58.0)	
Reader 2	54	11 (13.9)	43 (53.1)	
Reader 3	50	5 (6.3)	45 (55.6)	
Reader 4	32	2 (2.5)	30 (37.0)	
Negative				0.510 [0.447-0.573]
Reader 1	10	2 (2.5)	8 (9.9)	
Reader 2	40	8 (10.1)	32 (39.5)	
Reader 3	20	1 (1.3)	19 (23.5)	
Reader 4	37	5 (6.3)	32 (39.5)	

Notes: Qualitative variables are expressed as absolute and relative frequencies (n [%]). Percentages (%) shown are relative to the number of the respective category assigned within each group (i.e., COVID-19 and control) by each reader. The reported Fleiss kappa values are for all readers when all categories are considered simultaneously, as well as for each category individually.

Table 4 – RSNA diagnostic performance.

For COVID-19 pneumonia Criteria	AUC [95% CI]	Sensitivity (%) [95% CI]	Specificity (%) [95% CI]
Typical	0.781 [0.731-0.785]	52.2 [47.9-52.4]	98.5 [98.1-98.4]
Indeterminate	0.583 [0.579-0.598]	36.1 [35.8-38.9]	80.5 [79.2-80.7]
Typical or Indeterminate	0.865 [0.838-0.895]	88.3 [84.7-91.7]	79.0 [74.5-83.4]
For an Alternative Diagnosis Criteria	AUC [95% CI]	Sensitivity (%) [95% CI]	Specificity (%) [95% CI]
Atypical	0.742 [0.700-0.778]	50.8 [44.8-56.4]	93.4 [90.2-96.0]
Negative	0.646 [0.598-0.688]	28.4 [23.6-53.8]	94.8 [71.7-97.2]
Atypical or Negative	0.865 [0.838-0.895]	79.0 [74.5-83.4]	88.3 [84.7-91.7]

AUC = area under the curve; COVID-19 = coronavirus disease 2019.

231 pre-pandemic controls. Moreover, an atypical or negative pat-
 232 tern suggests an alternative diagnosis, but should be inter-
 233 preted with caution, as it does not rule out COVID-19
 234 diagnosis, nor the possibility of COVID-19 pneumonia. In
 235 addition, different possible diagnostic thresholds for COVID-
 236 19 pneumonia were explored, attaining one of high specificity
 237 and another of high sensitivity, with typical pattern only and
 238 typical plus indeterminate patterns combined, respectively.

239 Using pre-pandemic controls, that is, true negatives,
 240 results agree with the current body of evidence showing, as
 241 already mentioned, good correlation between the RSNA clas-
 242 sification and the RT-PCR results, as well as a consistent
 243 inter-reader agreement. Moreover, two possible diagnostic
 244 thresholds that could be interpreted and used according to
 245 specific clinical context needs were analyzed.

246 We ascertained the role of RSNA-proposed CT patterns for
 247 COVID-19 pneumonia diagnosis, especially the strong associ-
 248 ation between the typical pattern and COVID-19 pneumonia
 249 and between the atypical pattern and an alternative

250 diagnosis. Moreover, we propose that the two possible diag-
 251 nostic thresholds may aid in clinical decision-making consid-
 252 ering their advantages in specific contexts, primarily
 253 combined with the reference test, but also particularly helpful
 254 when the reference test is scarcely or not readily available.
 255 The typical pattern was highly specific and thus strongly sug-
 256 gestive of COVID-19 pneumonia diagnosis against a differen-
 257 tial diagnosis that could demand a different management.
 258 Both typical and indeterminate patterns for a positive test
 259 were highly sensitive, thus considering retesting following an
 260 initial negative RT-PCR result as well as to streamline early
 261 management and isolation until a definitive diagnosis can be
 262 made.

263 Our study has limitations, including the usual profile of
 264 the hospitalized patient population at our institution, whose
 265 normally high prevalence of admissions due to chronic condi-
 266 tions (e.g., heart failure, cancer) may be related to the statisti-
 267 cally significant difference in the presence of pneumonia/
 268 respiratory signs and symptoms between the two groups.




Fig. 1 – Receiver operating characteristic (ROC) curve for the possible coronavirus disease 2019 (COVID-19) pneumonia positivity criteria evaluated.



Fig. 2 – Typical CT imaging features for COVID-19 pneumonia. Axial unenhanced CT image of the lungs in a 61-year-old man with a positive RT-PCR showing bilateral, multifocal rounded and peripheral GGO.



Fig. 3 – Indeterminate CT imaging features for COVID-19 pneumonia. Axial contrast-enhanced chest CT image of the lungs in a 41-year-old female with a positive RT-PCR, showing bilateral widespread GGO with nonrounded morphology and no specific distribution with areas of consolidation.

269 Another possible reason is the undervaluation of said symp-
 270 toms in the pre-pandemic context, especially when of mild or
 271 vague nature, or even when linked with chronic conditions.
 272 Nevertheless, differential diagnosis is not restricted to infec-
 273 tions of obvious presentation or of infectious etiology,⁴ which
 274 in our opinion justifies the inclusion of patients without
 275 explicitly reported signs/symptoms. We also recognize that
 276 there is concern that the control patients and settings do not
 277 ideally match the review question, but we understand that it
 278 is an unavoidable issue given the case-control selection
 279 nature of the study. The limit of seven days between RT-PCR
 280 sampling and CT scanning for the COVID-19 group may also

be of concern, but it was necessary as CT scans were reserved 281
 for selected cases and often not immediately ordered in 282
 agreement with the institutional protocol and the principle of 283
 justification in a broad perspective, as RT-PCR testing was 284
 readily available and rapidly processed in-house. Finally, a 285
 fair Fleiss kappa-value was found for the indeterminate clas- 286
 sification, possibly related to the intrinsic unspecificity of its 287
 imaging findings, magnified by the use of four readers; how- 288
 ever, further analysis is necessary for clarification. 289

In conclusion, when tested against pre-pandemic controls, 290
 the RSNA classification system for reporting COVID-19 291




Fig. 4 – Atypical CT imaging features for COVID-19 pneumonia. Axial unenhanced chest CT image of the lungs in a 37-year-old control patient showing tree-in-bud opacities and centrilobular nodules, caused by active tuberculosis.

Table 5 – Predictive values.

For COVID-19 Pneumonia		
Criteria	PPV (%) [95% CI]	NPV (%) [95% CI]
Typical	97.3 [94.2-99.4]	67.9 [63.1-72.0]
Indeterminate	64.1 [56.1-71.2]	56.2 [51.6-60.7]
Typical or Indeterminate	80.5 [76.4-85.0]	87.4 [83.4-91.2]
For an Alternative Diagnosis		
Criteria	PPV (%) [95% CI]	NPV (%) [95% CI]
Atypical	88.7 [83.7-92.9]	65 [60.6-69.5]
Negative	84.7 [66.7-91.4]	56.6 [53.0-60.9]
Atypical or Negative	87.4 [83.4-91.2]	80.5 [76.4-85.0]

Note: Table shows the predictive values of different diagnostic criteria of the RSNA Classification for COVID-19 pneumonia and for an alternative diagnosis.

292 pneumonia showed prominent diagnostic performance, in
 293 agreement with the current literature, with potentially high
 294 specificity and sensitivity provided by its different diagnostic
 295 thresholds. Thus, we believe it can be an important aid in
 296 clinical decision-making, especially when a typical or indeter-
 297 minate pattern is found, considering retesting following an
 298 initial negative RT-PCR and streamlining early management
 299 and isolation.

300 Conflicts of interest

301 The authors declare no conflicts of interest.

302 REFERENCES

303 1. Center for Systems Science and Engineering. COVID-19
 304 dashboard by the Center for Systems and Engineering at Johns
 305 Hopkins University. Available at: [https://coronavirus.jhu.edu/
 306 map.html](https://coronavirus.jhu.edu/map.html) [accessed August 10, 2021].

2. Rubin GD, Ryerson CJ, Haramati LB, et al. The role of chest 307
 imaging in patient management during the covid-19 308
 pandemic: a multinational consensus statement from the 309
 fleischner society. *Radiology*. 2020;296:172–80. [https://doi.org/](https://doi.org/10.1148/radiol.2020201365) 310
[10.1148/radiol.2020201365](https://doi.org/10.1148/radiol.2020201365). 311
3. WHO Guidance Note. Use of chest imaging in COVID-19: a 312
 rapid advice guide. World Health Organization (WHO); 2020. 313
 Available at: [https://www.who.int/publications/i/item/use-of-
 chest-imaging-in-covid-19](https://www.who.int/publications/i/item/use-of-chest-imaging-in-covid-19) [accessed August 10, 2021]. 314
 315
4. Parekh M, Donuru A, Balasubramanya R, Kapur S. Review of 316
 the chest CT differential diagnosis of ground-glass opacities in 317
 the COVID era. *Radiology*. 2020;E289–302. [https://doi.org/](https://doi.org/10.1148/radiol.2020202504) 318
[10.1148/radiol.2020202504](https://doi.org/10.1148/radiol.2020202504). 319
5. Simpson S, Kay FU, Abbara S, et al. Radiological Society of 320
 North America expert consensus document on reporting chest 321
 CT findings related to COVID-19: endorsed by the Society of 322
 Thoracic Radiology, the American College of Radiology, and 323
 RSNA. *Radiol Cardiothorac Imaging*. 2020;2:e200152. [https://](https://doi.org/10.1148/ryct.2020200152) 324
doi.org/10.1148/ryct.2020200152. 325
6. Prokop M, Van Everdingen W, Van Rees Vellinga T, et al. CO- 326
 RADS: a categorical CT assessment scheme for patients 327
 suspected of having COVID-19 - definition and evaluation. 328
Radiology. 2020;296:E97–104. [https://doi.org/10.1148/](https://doi.org/10.1148/radiol.2020201473) 329
[radiol.2020201473](https://doi.org/10.1148/radiol.2020201473). 330
7. Johnstone A. Thoracic imaging in COVID-19 infection: 331
 guidance for the reporting radiologist. *Br Soc Thorac Imaging*. 332
 2020. Available at: [https://www.bsti.org.uk/media/resources/](https://www.bsti.org.uk/media/resources/files/BSTI_COVID-19_Radiology_Guidance_version_2_16.03.20.pdf) 333
[files/BSTI_COVID-19_Radiology_Guidance_version_2_16.03.20.](https://www.bsti.org.uk/media/resources/files/BSTI_COVID-19_Radiology_Guidance_version_2_16.03.20.pdf) 334
[pdf](https://www.bsti.org.uk/media/resources/files/BSTI_COVID-19_Radiology_Guidance_version_2_16.03.20.pdf) [accessed February 16, 2021]. 335
8. Byrne D, Neill SBO, Müller NL, et al. RSNA expert consensus 336
 statement on reporting chest CT findings related to COVID-19: 337
 interobserver agreement between chest radiologists. *Can* 338
Assoc Radiol J. 2021;72:159–66. [https://doi.org/10.1177/](https://doi.org/10.1177/0846537120938328) 339
[0846537120938328](https://doi.org/10.1177/0846537120938328). 340
9. Hadied MO, Patel PY, Cormier P, et al. Interobserver and 341
 intraobserver variability in the CT assessment of COVID-19 342
 based on RSNA consensus classification categories. *Acad* 343
Radiol. 2020;27:1499–506. [https://doi.org/10.1016/j.](https://doi.org/10.1016/j.acra.2020.08.038) 344
[acra.2020.08.038](https://doi.org/10.1016/j.acra.2020.08.038). 345
10. O' Neill SB, Byrne D, Müller NL, et al. Radiological Society of 346
 North America (RSNA) expert consensus statement related to 347
 chest CT findings in COVID-19 versus CO-RADS: comparison 348
 of reporting system performance among chest radiologists 349
 and end-user preference. *Can Assoc Radiol J*. 350
 2020;084653712096891. [https://doi.org/10.1177/](https://doi.org/10.1177/0846537120968919) 351
[0846537120968919](https://doi.org/10.1177/0846537120968919). 352
11. Inui S, Kurokawa R, Nakai Y, et al. Comparison of chest CT 353
 grading systems in COVID-19 pneumonia. *Radiol Cardiothorac* 354
Imaging. 2020;2:e200492. [https://doi.org/10.1148/](https://doi.org/10.1148/ryct.2020200492) 355
[ryct.2020200492](https://doi.org/10.1148/ryct.2020200492). 356
12. Som A, Lang M, Yeung T, et al. Implementation of the 357
 Radiological Society of North America expert consensus 358
 guidelines on reporting chest CT findings related to COVID-19: 359
 a multireader performance study. *Radiol Cardiothorac* 360
Imaging. 2020;2:e200276. [https://doi.org/10.1148/](https://doi.org/10.1148/ryct.2020200276) 361
[ryct.2020200276](https://doi.org/10.1148/ryct.2020200276). 362
13. Grando RD, Brentano VB, Zanardo AP, et al. Clinical usefulness 363
 of tomographic standards for COVID-19 pneumonia diagnosis: 364
 experience from a Brazilian reference center. *Brazilian J Infect* 365
Dis. 2020;24:524–33. <https://doi.org/10.1016/j.bjid.2020.10.002>. 366
14. Ciccicarese F, Coppola F, Spinelli D, et al. Diagnostic accuracy of 367
 North America Expert Consensus Statement on reporting CT 368
 findings in patients suspected of having COVID-19 infection: 369
 an italian single-center experience. *Radiol Cardiothorac* 370
Imaging. 2020;2:e200312. [https://doi.org/10.1148/](https://doi.org/10.1148/ryct.2020200312) 371
[ryct.2020200312](https://doi.org/10.1148/ryct.2020200312). 372
15. de Jaegere TMH, Krdzalic J, Fasen BACM, Kwee RM. 373
 Radiological Society of North America chest CT classification 374

- 375 system for reporting COVID-19 pneumonia: interobserver
376 variability and correlation with reverse-transcription
377 polymerase chain reaction. *Radiol Cardiothorac Imaging.*
378 2020;2:e200213. <https://doi.org/10.1148/ryct.2020200213>.
- 379 16. Barbosa PNVP, Bitencourt AGV, de Miranda GD, Almeida
380 MEA, Chojniak R. Chest CT accuracy in the diagnosis of
381 SARS-CoV-2 infection: initial experience in a cancer center.
382 *Radiol Bras.* 2020;53:211–5. <https://doi.org/10.1590/0100-3984.2020.0040>.
- 383
384 17. Kwee RM, Adams HJA, Kwee TC. Diagnostic performance of
385 CO-RADS and the RSNA classification system in evaluating
386 COVID-19 at chest CT: a meta-analysis. *Radiol Cardiothorac*
387 *Imaging.* 2021;3:e200510. <https://doi.org/10.1148/ryct.2021200510>.
- 388
389 18. Suchá D, van Hamersvelt RW, van den Hoven AF, de Jong PA,
390 Verkooijen HM. Suboptimal quality and high risk of bias in
391 diagnostic test accuracy studies at chest radiography and CT
392 in the acute setting of the COVID-19 pandemic: a systematic
393 review. *Radiol Cardiothorac Imaging.* 2020;2:e200342. <https://doi.org/10.1148/ryct.2020200342>.
- 394
395 19. Adams HJA, Kwee TC, Yakar D, Hope MD, Kwee RM.
396 Systematic review and meta-analysis on the value of chest CT
397 in the diagnosis of coronavirus disease (COVID-19): Sol
398 Scientiae, Illustra Nos. *Am J Roentgenol.* 2020;215:1342–50.
399 <https://doi.org/10.2214/AJR.20.23391>.
20. Mair MD, Hussain M, Siddiqui S, et al. A systematic review and
400 meta-analysis comparing the diagnostic accuracy of initial
401 RT-PCR and CT scan in suspected COVID-19 patients. *Br J*
402 *Radiol.* 2021;20201039. <https://doi.org/10.1259/bjr.20201039>.
- 403
404 21. Secretaria Estadual da Saúde. SES/RS - Coronavirus. Governo
405 Do Estado Do Rio Grande Do Sul, Brazil. Available at: <https://ti.saude.rs.gov.br/covid19/> [accessed November 18, 2021].
- 406
407 22. Secretaria Estadual da Saúde. Informe epidemiológico da
408 vigilância de influenza. Brazil: Governo Do Estado Do Rio
409 Grande Do Sul; 2018. Available at: <https://saude.rs.gov.br/upload/arquivos/201912/27150713-boletim-influenza-2018-06-09-1.pdf> [accessed November 18, 2021].
- 410
411 23. Fenn Buderer NM. Statistical methodology: I. Incorporating
412 the prevalence of disease into the sample size calculation for
413 sensitivity and specificity. *Acad Emerg Med.* 1996;3:895–900.
414 <https://doi.org/10.1111/j.1553-2712.1996.tb03538.x>.
- 415
416 24. Fleiss JL. Measuring nominal scale agreement among many
417 raters. *Psychol Bull.* 1971;76:378–82. <https://doi.org/10.1037/h0031619>.
- 418
419 25. Liu H, Wu T. Estimating the area under a receiver operating
420 characteristic (ROC) curve for repeated measures design. *J Stat*
421 *Softw.* 2003;8:1–18. <https://doi.org/10.18637/jss.v008.i12>.
- 422
423 26. Core Development Team R. A Language and Environment for
424 Statistical Computing, 2. R Found Stat Comput; 2020; <https://www.R-project.org>.